form8-k.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  April 25, 2014



CESCA THERAPEUTICS INC.
(Formerly Known As ThermoGenesis Corp.)
(Exact name of registrant as specified in its charter)


Delaware
  
000-16375
  
94-3018487
(State or other jurisdiction of incorporation or organization)
  
(Commission File Number)
  
(I.R.S. Employer Identification No.)

2711 Citrus Road
Rancho Cordova, California  95742
(Address and telephone number of principal executive offices) (Zip Code)

(916) 858-5100
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[  ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



 
- 1 -
 

Item 1.01 Entry into a Material Definitive Agreement

On April 25, 2014, the shareholders of Cesca Therapeutics Inc. (the “Company”),  as set forth below in Item 5.07, approved certain amendments to our Amended and Restated 2006 Equity Incentive Plan (“Amended Plan”) as previously disclosed in the Company’s proxy statement for its annual meeting held on April 25, 2014.  The full text of the Amended Plan is incorporated herein by reference and a copy of which is filed as Exhibit 10.6.1 hereto.

Item 5.03 Amendments to Articles of Incorporation or Bylaws

As set forth below in Item 5.07, on April 25, 2014, the shareholders of the Company also approved certain amendments to our Bylaws as previously disclosed in the Company’s proxy statement for its annual meeting held on April 25, 2014.  The full text of the Bylaws of the Company is incorporated herein by reference and a copy of which is filed as Exhibit 3.2.1 hereto.

Item 5.07 Submission of Matters to a vote of Security Holders.

On April 25, 2014, Cesca Therapeutics Inc. (the “Company”) held its annual meeting of stockholders (“Annual Meeting”) at 11211 Point East Drive, Rancho Cordova, California  95742, at 9:00 a.m. to vote on certain matters.  Pursuant to the votes discussed in further detail below, Craig W. Moore, Patrick J. McEnany, Mahendra S. Rao, Robin C. Stracey, Matthew T. Plavan and Kenneth L. Harris were elected to the board of directors.  Further, the amendments to the Bylaws pursuant to proposals 2, 3, and 5 were adopted, while proposal 4 (requirement that shareholder action only be taken at meetings) did not pass.  The proposals related to the amendments to the 2006 Equity Incentive Plan (proposal 6), executive compensation (proposal 7) and auditors (proposal 9) also passed.  Shareholders recommend by a non-binding advisory vote a one-year frequency of future non-binding advisory votes on the compensation of the Company’s named executive officers. The specific proposals are discussed in detail in the Company’s proxy statement dated April 4, 2014.


1.  
To elect six (6) directors to hold office until the next Annual Meeting of Stockholders or until their successors are elected and qualified.

 
 
Election of
Directors
  
 
For
  
 
Withhold
  
Broker
Non Votes
  
 
Craig W. Moore
  
15,752,622
  
767,785
  
8,325,321
  
 
Patrick J. McEnany
  
16,291,317
  
229,090
  
8,325,321
  
 
Mahendra S. Rao
  
16,382,842
  
137,565
  
8,325,321
  
 
Robin C. Stracey
  
16,308,962
  
211,445
  
8,325,321
  
 
Matthew T. Plavan
  
16,331,660
  
188,747
  
8,325,321
  
 
Kenneth L. Harris
  
16,354,112
  
166,295
  
8,325,321
  

2.  
To approve an amendment to our bylaws for clarifying certain administrative functions, including changing the name to Cesca Therapeutics Inc. and providing of notice and stockholder records electronically.

 
For
  
Against
  
Abstain
  
 
24,737,665
  
88,363
  
19,700
  

3.  
To approve an amendment to our bylaws to allow the number of directors to be set by the board.

 
For
  
Against
Abstain
  
 
14,051,034
  
10,539,065
  
91,155
  

4.  
To approve an amendment to our bylaws to eliminate stockholder action by written consent.

 
For
  
Against
  
Abstain
  
 
5,867,817
  
10,573,884
  
78,681
  

5.  
To approve an amendment to our bylaws to provide for a forum for adjudication of disputes.

 
For
  
Against
  
Abstain
  
 
23,815,361
  
721,746
  
144,147
  


6.  
To approve amendments to the 2006 Equity Incentive Plan.

 
For
  
Against
  
Abstain
  
 
15,348,162
  
1,096,222
  
76,023
  


7.  
To approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.

 
For
  
Against
  
Abstain
  
 
15,412,343
  
1,034,489
  
73,575
  

8.  
To recommend by a non-binding advisory vote the frequency of future non-binding advisory votes on the compensation of the Company’s named executive officers.

 
1 Year
  
2 Year
  
3 Year
  
Abstain
 
10,865,129
  
4,709,850
  
183,531
  
761,897

9.  
To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the 2014 fiscal year.

 
For
  
Against
  
Abstain
  
 
24,742,092
  
84,276
  
19,360
  


Item 9.01 Financial Statements and Exhibits

                  (d) Exhibits.


Exhibit No.
  
Exhibit Description
     
3.2.1
  
Bylaws of Cesca Therapeutics Inc.
     
10.6.1
  
Amended and Restated 2006 Equity Incentive Plan

 
- 2 -
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


   
Cesca Therapeutics Inc.
  
   
a Delaware Corporation
  
       
       
 
Dated:  May 1, 2014
/s/ Dan T. Bessey
  
   
Dan T. Bessey,
  
   
Chief Financial Officer
  
       

- 3 -